STOCK TITAN

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Viridian Therapeutics, Inc. announced the approval of non-qualified stock options for six new employees. The Inducement Grants were granted outside of the company's Equity Incentive Plan but are subject to its terms. The grants aim to attract new talent and were approved by independent directors. The options have an exercise price equal to the closing price of the company's common stock on the Grant Date and will vest over a four-year period.

Positive
  • None.
Negative
  • None.

WALTHAM, Mass.--(BUSINESS WIRE)-- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 551,000 shares of the company’s common stock to six new employees (the “Inducement Grants”) on May 1, 2024 (the “Grant Date”). The Inducement Grants have been granted outside of the company’s Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grants have an exercise price per share that is equal to the closing price of Viridian’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to each employee’s continued employment with Viridian through the applicable vesting dates.

About Viridian Therapeutics

Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED.

In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn and X.

Louisa Stone, 617-272-4604

Manager, Investor Relations

IR@viridiantherapeutics.com

Source: Viridian Therapeutics, Inc.

FAQ

What did Viridian Therapeutics announce?

Viridian Therapeutics announced the approval of non-qualified stock options for new employees.

When were the Inducement Grants approved?

The Inducement Grants were approved on May 1, 2024.

How many shares of the company's common stock were approved for purchase?

An aggregate of 551,000 shares of the company's common stock were approved.

What is the vesting period for the Inducement Grants?

The Inducement Grants will vest over a four-year period.

What is the purpose of the Inducement Grants?

The Inducement Grants were granted as an inducement for new employees entering into employment with Viridian.

What is the exercise price per share for the Inducement Grants?

The exercise price per share is equal to the closing price of Viridian's common stock on the Grant Date.

Viridian Therapeutics, Inc.

NASDAQ:VRDN

VRDN Rankings

VRDN Latest News

VRDN Stock Data

1.59B
76.37M
0.01%
112%
13.12%
Biotechnology
Services-medical Laboratories
Link
United States of America
WALTHAM